Abstract Disease risk-associated single nucleotide polymorphisms (SNPs) identified from genome-wide association studies (GWAS) have the potential to be used for disease risk prediction. An important feature of these riskassociated SNPs is their weak individual effect but stronger cumulative effect on disease risk. To date, a stable summary estimate of the joint effect of genetic variants on disease risk prediction is not available. In this study, we propose to use the graded response model (GRM), which is based on the item response theory, for estimating the individual risk that is associated with a set of SNPs. We compare the GRM with a recently proposed risk prediction model called cumulative relative risk (CRR). Thirty-three prostate cancer risk-associated SNPs were originally discovered in GWAS by December 2009. These SNPs were used to evaluate the performance of GRM and CRR for predicting prostate cancer risk in three GWAS populations, including populations from Sweden, Johns Hopkins Hospital, and the National Cancer Institute Cancer Genetic Markers of Susceptibility study. Computational results show that the risk prediction estimates of GRM, compared to CRR, are less biased and more stable.
Introduction
Prostate cancer (PCa) is highly heritable (Lichtenstein et al. 2000) and is the most common non-skin cancer among men in developed countries (Jemal et al. 2010 ). Genome-wide association studies (GWAS) for the past several years have successfully identified several PCa risk-associated single nucleotide polymorphisms (SNPs). Individually, these SNPs are moderately associated with the risk of PCa, having odds ratios (ORs) between 1.0 and 1.5 (Goldstein 2009). However, when combined together these SNPs have a stronger dose-dependent association (Zheng et al. 2008; Fitzgerald et al. 2009 ). This opens the possibility of using multiple SNPs for risk prediction.
The goal of risk prediction is to identify individuals at high risk of developing a disease and to guide therapeutic strategies. Recently, researchers have begun to use a combination of risk SNPs in the form of genetic scores to predict risk for complex diseases. Zheng et al. (2008) calculated a genetic score by summing up risk genotypes and then fitting a predictive model to the genetic score using logistic regression. A disadvantage of this approach is that it treats the genetic effect from each SNP equally. In addition, it uses the genetic score created from the same dataset (''internal data'') for prediction, which could lead to inflation in prediction accuracy. Kang et al. (2010) compared several methods for risk prediction, including logistic regression, random forests and support vector machine (SVM) . Depending on the data situation, one method outperformed the other but none was uniformly superior. The algorithms used for each approach relied heavily on the knowledge domain of the individual research team. Based on simulation results, logistic regression with weighted linear combination was slightly more powerful under most of the scenarios. Kim et al. (2010) conducted a metaanalysis of several studies to obtain the pooled estimate of OR for calculating the genetic score. This approach is similar to the weighted linear combination score, but the weight is obtained from the meta-analysis. The advantages of this meta-analysis include the use of SNP weight based on association with disease risk and that external data were used in the study. Newcombe et al. (2012) compared three different genetic scores including logistic regression with weighted linear combination, the meta-analysis approach, and the Bayesian logistic regression via informative priors from the external meta-analysis. They found that the last two methods that included external information performed equally best.
When a sum score of multiple biomarkers is used, the approach follows a classical test theory (CTT) approach which has been extensively used in educational and psychological testing. The CTT assumes that the sum score is an unbiased estimate of a true underlying risk score. The sum score approach is easily computed and is appropriate if the items (biomarkers) are equally weighted, if there is no missing data, and if individual biomarkers function uniformly across subpopulations. However, these assumptions do not necessarily hold true in genetic studies. As a proven methodology rooted in the psychometric literature, the item response theory (IRT) provides an alternative to the CTT-based sum score approach. One of the advantages of using IRT over CTT is that it takes into account the differential impact of individual biomarkers over different regions of the risk spectrum. It also provides a scientific framework for testing the validity of model assumption and evaluating theories. In this paper, we propose a method to calculate genetic scores based on an IRT framework. Particularly, we compare the IRTbased results with the genetic score that was generated using a meta-analysis frequentist approach . Three GWAS populations were used to evaluate the methods.
Methods

Study populations
Three PCa GWAS populations were utilized to explore the genetic effect of a set of SNPs on PCa. The first GWAS population, a population-based PCa case-control study from Sweden (CAPS), included 2,899 cases and 1,722 controls. The CAPS study has been described in detail elsewhere (Zheng et al. 2008) . Briefly, PCa patients in CAPS were identified and recruited from regional cancer registries in Sweden (all Caucasians). The inclusion criteria for cases were having pathologically or cytologically verified adenocarcinoma of the prostate and diagnosis between July 2001 and October 2003. DNA samples from blood and tumor-node-metastasis stage, Gleason grade (biopsy), and prostate-specific antigen (PSA) levels at diagnosis were available for 2,899 patients. Control subjects were recruited concurrently with case subjects, i.e., they were randomly selected from the Swedish Population Registry, and matched according to the expected age distribution of cases (groups of 5-year intervals) and geographic region. DNA samples from blood were available for 1,722 controls.
The second population was from the Johns Hopkins Hospital (JHH) which included 1,964 PCa cases and 3,172 controls. Cases consisted of Caucasian PCa patients who underwent radical prostatectomy for the treatment of PCa at JHH from January 1, 1999, through December 31, 2008 . Controls were an independent group of Caucasian individuals from the Illumina iControlDB (iControls) dataset (https://www.illumina.com/science/ icontrodb.ilmn).
The third population was obtained from Stage 1 of the National Cancer Institute Cancer Genetic Markers of Susceptibility (CGEMS, http://cgems.cancer.gov/) study. It included 1,176 PCa cases and 1,101 controls, selected from the Prostate, Lung, Colon and Ovarian (PLCO) Cancer Screening Trial (Thomas et al. 2008; Yeager et al. 2009 ).
Genotype data, imputation, and quality control
We selected a set of 33 PCa risk-associated SNPs, each of which was originally identified in GWAS by December 2009, with p \ 10 -7 and for which associations have been confirmed in independent studies (Amundadottir et al. 2006; Gudmundsson et al. 2007a, b; Yeager et al. 2007 Yeager et al. , 2009 Duggan et al. 2007; Thomas et al. 2008; Eeles et al. 2008 Eeles et al. , 2009 . The CGEMS population was used to discover 6 out of the 33 SNPs (Thomas et al. 2008; Yeager et al. 2007 Yeager et al. , 2009 . The CAPS population was used to discover 4 out of the 33 SNPs (Sun et al. 2008 Hsu et al. 2009; Zheng et al. 2009 ). The JHH population was not used in the initial discovery population. Genotyping of the CAPS population was performed using the Affymetrix 5.0 chip. Genotyping of the JHH case population was performed using the Illumina 610K chip . Genotyping of the iControl population (http://www.illumina.com/ science/icontrodb.ilmn) was performed using Illumina Hap300 and Hap550 Chips. Genotyping of the CGEMS population was performed using HumanHap300 and HumanHap240 assays from Illumina Corp.
All of the known SNPs catalogued in HapMap Phase II (http://www.hapmap.org) were imputed using the IMPUTE computer program (Marchini et al. 2007 ) with a posterior probability of 0.9 as a threshold to call genotypes. Individuals with a call rate below 0.95 were removed from the analysis. All of the SNPs had a minor allele frequency (MAF) greater or equal to 0.01 and passed a HardyWeinberg equilibrium test (p C 0.001). The call rates were all greater or equal to 0.95.
Genetic score generated using meta-analysis Meta-analysis-based genetic score assigns a score for each SNP using OR estimates from multiple studies (Lango et al. 2008; Lin et al. 2009; Kim et al. 2010; Paynter et al. 2010) . The details of the calculation are described elsewhere . Briefly, a literature search was performed and information regarding the 33 SNPs was retrieved and related references were reviewed. If raw data (e.g., allele counts of case and control) were available, they were used to calculate the allelic OR and its standard error for each study population. If they were not available, the reported OR and 95 % CI were used. Heterogeneity across studies was evaluated using Q statistic and I 2 statistic. If there was no evidence for heterogeneity (p [ 0.05 and I 2 \ 50 %), then a meta-analysis using the fixed effects method was performed to calculate the pooled estimate of OR and confidence interval for each SNP. On the other hand, a random effects model for pooled OR calculation was used if evidence for heterogeneity was observed. Table 1 shows the effect estimates from meta-analysis (allelic odds ratios with 95 % confidence intervals) for the selected 33 SNPs, heterogeneity result, and their corresponding missing rates in the three GWAS populations. Note that, one SNP-rs16902094 in CGEMS, and three SNPs-rs620861, rs16902094 and rs5945619 in JHH were not available for performing this analysis.
For each of the genotypes within a SNP, the allelic OR was converted to the relative risk (RR). Here the RR was approximated using OR. Allelic frequency was obtained from the CEU (Utah residents with Northern and Western European ancestry from the CEPH collection) of the HapMap database. Genotypic RRs were estimated from allelic RR using a multiplicative model. Population risk for PCa was calculated by summing risks (genotypic OR 9 genotypic frequency) of all three genotypes. Risk of each genotype relative to population risk was calculated as the RR of each genotype divided by population risk. Assuming a multiplicative model among SNPs, an individual cumulative RR (CRR) was calculated by multiplying the risk of each SNP of specific genotype of this individual for the 33 PCa riskassociated SNPs.
Item response theory and graded response model IRT (Lord 1980; Baker and Kim 2004 ) considers a class of models that link dichotomous and polytomous response variables to a single latent variable. The main applications of IRT can be found in educational testing in which analysts are interested in measuring examinees' ability using tests that consist of multiple items. The Graded Response Model (GRM, Samejima 1969 ) is an IRT model specifically designed for K ordered polytomous responses. In this study, there are three (K = 3) ordered genotype categories for each SNP and they could be as follows: Y = 0 (no risk allele), Y = 1 (one risk allele) and Y = 2 (two risk alleles). We use h-a continuous latent variable-to denote the general risk level of an individual for PCa. Mathematically, the GRM model is specified by the following SNP response function:
where a i and b ik are, respectively, the discrimination and category-specified parameter of SNP i, and PðY i ! kjhÞ denotes the cumulative probability of genotype categories k or higher for the ith SNP, given the risk h. Because GRM requires b i1 \b i2 \ Á Á Á \b iK , the probability of each genotype category is thus given by: Figure 1 shows the SNP characteristic function and information (one over the variance of the estimator h) function of SNP rs6983267 from CGEMS data set. The horizontal axis (h) represents the overall risk score of an individual, and the left-hand side vertical axis represents the probability of observing a particular genotype category, and the right-hand side vertical axis represents the information. Conventionally, the category-specified parameter b ik determines the relative position of the corresponding curve on the risk spectrum, and the parameter a i determines the steepness of the curves for the extreme categories and the sharpness of the middle categories. The curves in Fig. 1 do not resemble characteristic functions and information function commonly seen in educational and psychological study. Compared to their educational counterparts, the parameter a i was generally smaller, implying a low level of information that can be gleaned from an individual SNP.
In this study, a ''constrained'' GRM model was adopted. This means that the discrimination parameter a i for each SNP was forced to be the same across the categories. A R-based program ltm (Rizopoulos 2006 ) was used to estimate SNP parameters and risk scores for each data set. Applying the GRM model to a given data set, a genetic score for each individual could be estimated. As a summary measure of SNPs, the genetic score can be included as a covariate in a predictive model for examining the association between genes and disease risk. Using the current application as an example, instead of including all of the 33 SNPs in the model, we only need to include the summary measure. The regression model would be more parsimonious and the estimate of regression coefficient would be more precise.
Evaluation
To assess the performance of CRR and GRM in discriminating between cases and controls, we used the area under a curve (AUC) statistic of the receiver operating characteristic (ROC) to assess the overall performance of estimated genetic scores. Because summarizing the ROC curve into a single AUC number may lose information about the pattern of tradeoffs of the particular classifier, we augmented AUC with two commonly used criteria of selecting 
where P, N, TP, and TN are positive, negative, true positive and true negative values, respectively. Cross-validations were performed to evaluate the robustness of the CRR and GRM approach based on the ''best'' cutoff. For example, the best cutoff of CAPS served as the cutoff for the other two data sets for classification analysis. Note that the RR of each SNP was obtained from a metaanalysis, and was applied directly to each data set to calculate CRR. However, the SNP parameters estimated by GRM were based on the same data set in which this approach was applied. To make a fair comparison, another cross-validation was performed to evaluate the robustness of GRM based on different sets of SNP parameter estimates. For example, the GRM scores of CAPS are estimated using estimated SNP parameters from the JHH (or CGEMS) data. Figure 2 shows the ROC and the corresponding AUC for each of the three data sets. Here, the GRM score was estimated using the estimated SNP parameters from each individual data set. Based on the AUC values shown in Fig. 2 , GRM is comparable to CRR for the data sets CAPS and CGEMS, but slightly weaker than CRR for discriminating between PCa cases and controls in JHH. We further investigated the GRM and CRR scores by examining the case/control distributions with respect to GRM and CRR scores for three data sets (Fig. 3) . The shapes of the distributions with respect to CRR and GRM are rather similar for all data sets. However, the modes of case and control distributions are more separable in GRM scores. Thus, GRM score is more favorable than CRR score in between cases and controls. Figure 4 shows the scatter plots of CGM versus CRR scores for CAPS, JHH, and CGEMS, respectively. The correlations between the CGM and CRR scores of CAPS, JHH and CGEMS are 0.76, 0.80 and 0.83, respectively. They are highly correlated. Note that the distributions of CRR scores are very different among these three populations, whereas the GRM scores fall within a range from -1.5 to ?1.5.
Results
The cutoffs based on ACC and BAC for classification in these three populations are presented in Table 2 , along with the TN rate (= TN N , control), the TP rate (= TP P , case), ACC and BAC. Because CAPS and JHH consist of imbalanced data (i.e., different numbers of cases and controls), the corresponding cutoffs based on ACC resulted in bias for both CRR and GRM as classifiers (either favoring cases or controls), although both yield higher ACC. In such cases, it is not fair to compare CRR and GRM. In contrast, cutoffs based on maximizing BAC produced more reliable classification results for both CRR and GRM, with the exception of CRR score in CEGEMS. Overall, except for the JHH data, the performance of GRM based on maximizing BAC was slightly better than CRR in terms of both ACC and BAC.
The selection of cutoff is a crucial issue in classification. Table 3 shows the cross-validation results of CRR based on the best cutoff by maximizing either ACC or BAC. The term ''cross-validation'' refers to a procedure that used the ''best cutoff'' based on the classification performance of one data set, and then applied the same cutoff to the other data sets to evaluate their classification performance. For example, the first block under ''CAPS cutoff (1.2563)'' in Table 3 reports the classification performance of the best cutoff, 1.2563, of CRR from CAPS for calculating the ACC and BAC for JHH and CGEMS. The variations of ACC (or BAC) among each dataset across the three cutoffs are not large; however, the TP and TN rates are dramatically different across these three data sets. For example, when the cutoff of 0.9695 was used to replace the cutoff of 1.2563, the TN and TP rates for CAPS changed from 69.16 and 48.57 % to 52.96 and 63.37 %, respectively. As mentioned earlier, the range of CRR scores are very different across the three data sets. This implies that the cutoff for CRR is highly data dependent. Furthermore, the resulting TP and TN rates are also sensitive to the cutoff selection.
On the other hand, we observed that GRM scores for each population are symmetrically distributed and centered at 0, as GRM assumes that h follows a standard normal distribution. As a result, it is natural to set 0 as the cutoff when using a GRM score for prediction. Table 4 presents the cross-validation of GRM by setting the cutoff at 0 for all data sets. Here, the ''cross-validation'' procedure not only used the same cutoff-i.e. zero-to all data sets, but it also applied the SNP parameters estimated by each dataset to estimate the score across all three data sets. For example, the values for the ACC and BAC pair (58.04 %, 58.22 %) in the third column under CAPS/JHH in Table 4 were calculated using the SNP parameters from JHH to estimate the GRM score for CAPS. The variations of ACC, BAC, TP and TN rates for each dataset, resulting from the use of different sets of estimated SNP parameters, are smaller than those shown in Table 3 for the CRR score. In contrast to results reported in Table 2 , GRM resulted in a slight loss of accuracy (ACC or BAC) when setting the cutoff at 0. However, results from cross-validation demonstrate the robustness (less bias and more stable TP and TN rates) of using 0 as the cutoff instead of using maximized ACC or BAC criteria to determine the cutoff, which are data dependant.
Discussion
We propose to use an IRT-based procedure, the GRM, to estimate genetic risk scores. The idea of genetic risk score estimation can be viewed as analogous to the ability (score) estimations using individual item responses (risk allele categories) on a set of test items (SNPs). To our knowledge, this is the first report to apply IRT to genetic risk prediction. We compared GRM with the CRR approach, which is based on meta-analysis. Using AUC as a performance measure, GRM is comparable to CRR. However, further examination revealed the instability of CRR. Most importantly, the current study demonstrated the robustness and replicability of using GRM scores for risk prediction. The practical implication of the result is that the genetic score based on GRM is a reliable and serious competitor for risk prediction. Our findings are also relevant to a wide range of gene-disease associations.
Unlike CRR or machine learning approaches, GRM does not directly use phenotypic information for building a prediction model. As a result, GRM should be expected to demonstrate less discriminatory power than machine learning approaches. As a member of a general class of non-linear mixed effects models, the GRM can incorporate phenotypic information. However, it is not clear that such an addition could improve the utility of genetic risk prediction. The incorporation of phenotypic information into GRM is worth further research efforts. Besides conventional regression methods for risk prediction, machine learning approaches can also be used. However, issues such as feature selection and application-specific algorithm tuning make it difficult for researchers to successfully replicate results. The current adoption of GRM follows a ''risk allele'' (allelic OR) idea that is similar to CRR. The major difference between these approaches is that GRM estimates the ''overall'' risk based on the estimated SNP parameter of a data set, while CRR involves the multiplication of ''individually'' estimated RRs of SNPs from the meta-analysis of several data sets. A limitation of this study was the use of a panel of preselected SNPs. GWAS with more complete genome coverage using a case-control design will likely identify additional SNPs associated with PCa. In this study, we did not provide any SNP selection mechanism; the 33 SNPs evaluated here were merely based on scientific papers identified by December 2009. Like meta-analysis, the GRM approach described here might miss potentially important SNPs in the remainder of the genome for PCa risk detection. On the other hand, there might also be some SNPs among the pre-selected 33 SNPs that have negligible contribution to risk score in one or more of our study samples. In order to more fairly compare both CRR and GRM approaches, we performed analyses using the same pre-selected SNPs for both methods.
The strengths of IRT-based risk estimation can be summarized as follows. First, the IRT-based procedure supports the use of incomplete SNP information and it can handle missing data. The GRM score can be derived from any subset of SNPs of which SNP parameters are known. This is a great advantage when missing genotypes occur, which is not uncommon. Second, unlike CRR, it does not require a complex procedure for calculating the weighting of each SNP derived from meta-analysis. Third, it offers a more reliable and robust risk prediction model-a classifier with cutoff selection that is not data set dependent. Fourth, it allows a description of the relationship between SNP parameters for each individual SNP and risk spectrum, which can help to explain the genetic effect and molecular mechanism of individual SNP. Note that the SNP parameters in this study should provide a less informative description of the relationship between individual SNP and disease risk than unconstrained GRM does. The commonly used SNP characteristic function, normal ogive and logistic, could make unconstrained GRM very unstable and even to collapse (Thissen and Steinberg 1986) . It is possible to adopt other SNP characteristic function in unconstrained GRM for avoiding instability. While this study largely focused on the capability of the GRM score for risk prediction, further studies on unconstrained GRM could further explore this relationship.
In summary, an IRT-based procedure, the GRM, was introduced to estimate genetic risk scores. Computational results show that the risk prediction estimates of GRM, compared to CRR, are less biased and more stable. This approach has several advantages and can be applied in genetic risk prediction more widely in the future. 
